New drug targets Hard-to-Treat cancers with missing gene

NCT ID NCT06810544

Recruiting now Disease control Sponsor: Tango Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called TNG456, alone or with another drug (abemaciclib), in people with advanced cancers that have lost a gene called MTAP. The trial has two parts: first finding a safe dose, then testing how well it shrinks tumors. Up to 191 adults with lung cancer, brain tumors, or other solid tumors that have progressed on standard treatments may join.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TNG456 (a PRMT5 inhibitor) and abemaciclib (Verzenio)
What this could lead to: If successful, this could lead to a new treatment option for certain hard-to-treat cancers that have an MTAP gene loss.
What could go wrong: This is an early first-in-human study, so safety and effectiveness are not yet known. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm glioblastoma glioma lung adenocarcinoma lung cancer lung neoplasm malignant glioma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR GLIOMA GLIOBLASTOMA MULTIFORME GLIOMA, MALIGNANT LUNG CANCER NON-SMALL CELL ADENOCARCINOMA NON-SMALL CELL LUNG CANCER SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mayo Clinic Cancer Center
RECRUITING

Rochester, Minnesota, 55905-0001, United States
Mayo Clinic Jacksonville
RECRUITING

Jacksonville, Florida, 32224, United States
Mayo Clinic Scottsdale
RECRUITING

Scottsdale, Arizona, 85259-5452, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 11065, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
NYU Langone Health
RECRUITING

New York, New York, 10016, United States
Northwestern Memorial Hospital
RECRUITING

Chicago, Illinois, 60611-2908, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
Sibley Memorial Hospital
RECRUITING

Washington D.C., District of Columbia, 20016, United States
University of California Los Angeles
RECRUITING

Los Angeles, California, 90995, United States
University of California at San Francisco
RECRUITING

San Francisco, California, 94143-2202, United States
University of California, Irvine
RECRUITING

Irvine, California, 92686, United States
University of Utah, Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112-5500, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.